Last edition
News about Global Pharma
Quotient Sciences and CPI to Form JV to Accelerate RNA Drug Development
Quotient Sciences and UK innovation centre CPI have signed an MoU to form a joint venture that will accelerate the development of RNA-based therapies through an integrated, end-to-end platform.
Global Pharma | 03/09/2025 | By Mrinmoy Dey | 276
SeqOne Strengthens UK Presence with Acquisition of Congenica
The acquisition of UK genomics leader Congenica strengthens SeqOne’s market position and global footprint, servicing over 160 labs in more than 30 countries.
Global Pharma | 03/09/2025 | By Dineshwori | 155
LOTTE BIOLOGICS Enters Contract Manufacturing Partnership with US Biopharma
South Korea’s LOTTE BIOLOGICS has signed a late-stage to commercial contract manufacturing agreement with a US-based global biopharmaceutical company.
Global Pharma | 02/09/2025 | By Dineshwori | 461
Servier and IDEAYA Biosciences have entered into an exclusive license agreement to globally develop and commercialise darovasertib, a potential first-in-class therapy for uveal melanoma, with Servier taking rights outside the US and IDEAYA retaining US rights.
Global Pharma | 02/09/2025 | By Mrinmoy Dey | 237
Remedium Lifecare Unveils 4-Point Growth Strategy
Remedium Lifecare Ltd. has unveiled a 4-point strategic roadmap – spanning advanced manufacturing, global expansion, R&D innovation, and product diversification.
Global Pharma | 02/09/2025 | By Mrinmoy Dey | 185
Asston Pharmaceuticals Secures International Supply Order Worth INR 2.65 Crore
Asston Pharmaceuticals has received an order from a leading international pharmaceutical company to supply a range of pharma products worth INR 2.65 crore
Global Pharma | 02/09/2025 | By Dineshwori | 228
Four Drugs in Race for First Bispecific ADC Approval: GlobalData
With 21 global approvals, ADCs generated USD 13.6 billion in 2024. BsADCs represent further opportunities in this field, by leveraging bi-specific antibodies that simultaneously bind two distinct targets.
Global Pharma | 02/09/2025 | By Dineshwori | 320
Accro Bioscience and Fosun Pharma Enter Licensing Deal for AC-201 in Greater China
Accro Bioscience has granted Fosun Pharma exclusive rights to develop, manufacture, and commercialise AC-201 — its independently developed, highly selective TYK2/JAK1 inhibitor — in Greater China (including the Chinese Mainland, Hong Kong SAR, and Macau SAR).
Global Pharma | 01/09/2025 | By Dineshwori | 323
Bausch Health Expands Dermatology Portfolio with YUN Probiotherapy Launch in Poland
Following its partnership with Belgian biotech company YUN NV last June, Bausch Health has launched the YUN ACN skincare line in Poland, expanding its dermatology portfolio.
Global Pharma | 01/09/2025 | By Dineshwori | 526
FDA Approves Eisai and Biogen's At-Home Alzheimer's Injection Leqembi IQLIK
Leqembi IQLIK, delivering a 360 mg dose within 15 seconds, will be available from 6 October, 2025, at a list price of USD 19,500 annually for a pack of pre-filled autoinjectors.
Global Pharma | 30/08/2025 | By Dineshwori | 592
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy